Your session is about to expire
← Back to Search
Behavioral Intervention
Operant Conditioning for Phantom Limb Pain (OCS-PLP Trial)
N/A
Recruiting
Led By Jodi A Brangaccio, PT
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
An upper (or lower limb) amputation more than 6 months ago, that has produced a moderate to severe hand/arm (or foot/leg) phantom limb pain
Be older than 18 years old
Must not have
Presence of other medically unstable condition (e.g., uncontrolled diabetes with recent weight loss, diabetic coma, frequent insulin reactions)
Cognitive and/or attention difficulties affecting participant's ability to follow study directions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, end of training (session 20) i.e. approximately 10 weeks from baseline, follow-up at 3-months after training ends, follow-up at 6-months after training ends
Awards & highlights
No Placebo-Only Group
Summary
This trial will investigate a new way to reduce phantom limb pain, which affects 60-90% of amputees. The approach uses realtime feedback of brain responses to promote normal sensorimotor reorganization. Goal: reduce PLP & its effects.
Who is the study for?
This trial is for adults over 18 who've had an arm or leg amputated more than 6 months ago and suffer from moderate to severe phantom limb pain. They should be stable on current medications, if any, able to follow study instructions, and have medical clearance. Those with heart conditions, unstable health issues like uncontrolled diabetes, cognitive difficulties, skin disorders at the EEG site, or metal implants above the chest cannot join.
What is being tested?
The study tests a non-drug technique called operant conditioning alongside peripheral stimulation to reduce phantom limb pain in amputees. Participants will receive real-time brain feedback aimed at normalizing sensorimotor responses. The control group receives only peripheral stimulation without this targeted brain training.
What are the potential side effects?
Since it's a non-pharmacological approach focusing on behavioral therapy and electrical stimulation of nerves through the skin (peripheral), side effects might include discomfort or skin irritation where electrodes are placed for EEG recording and peripheral stimulation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had an arm or leg amputation over 6 months ago and suffer from severe phantom limb pain.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any uncontrolled medical conditions like severe diabetes.
Select...
I have trouble focusing or remembering, which may affect my ability to follow study instructions.
Select...
I do not have any skin issues or wounds on my scalp where an EEG would be placed.
Select...
I have a history of heart problems like heart attack or heart failure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, end of training (session 20) i.e. approximately 10 weeks from baseline, follow-up at 3-months after training ends, follow-up at 6-months after training ends
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, end of training (session 20) i.e. approximately 10 weeks from baseline, follow-up at 3-months after training ends, follow-up at 6-months after training ends
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Pain as Measured by the Short form-McGill Pain Questionnaire (SF-MPQ)
Change in Somatosensory Evoked Potential (SSEP) Amplitude as Measured by a Tactile Event Related Potential Test
Change in Somatosensory Evoked Potential (SSEP) Latency as Measured by a Tactile Event Related Potential Test
Secondary study objectives
Change in Impact of Pain on Quality of Life as Measured by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Intervention GroupExperimental Treatment1 Intervention
Intervention group receives peripheral stimulation with realtime operant conditioning feedback training.
Group II: Control GroupExperimental Treatment1 Intervention
Control group receives peripheral stimulation but without operant conditioning feedback.
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,846 Total Patients Enrolled
42 Trials studying Chronic Pain
5,152 Patients Enrolled for Chronic Pain
Jodi A Brangaccio, PTPrincipal InvestigatorAlbany VA Medical Center Samuel S. Stratton, Albany, NY
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I do not have any uncontrolled medical conditions like severe diabetes.I have trouble focusing or remembering, which may affect my ability to follow study instructions.I can follow the study's required procedures.I do not have any skin issues or wounds on my scalp where an EEG would be placed.I have a history of heart problems like heart attack or heart failure.My current medications are expected to stay the same for the next 4 months.I had an arm or leg amputation over 6 months ago and suffer from severe phantom limb pain.You have metal implants in your body above your chest.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention Group
- Group 2: Control Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.